Intellia Therapeutics (NTLA) Other Non-Current Liabilities (2015 - 2022)
Intellia Therapeutics' (NTLA) quarterly Other Non-Current Liabilities came in at $24.0 million in Q4 2022, up 29.17% on a QoQ basis from $18.6 million in Q3 2022.
Intellia Therapeutics (NTLA) Other Non-Current Liabilities (2015 - 2022) Analysis & Trends
Intellia Therapeutics (NTLA) has 5 years of Other Non-Current Liabilities data on file, last reported at $24.0 million in Q4 2022.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $24.0 million in Q4 2022; TTM through Dec 2022 was $24.0 million, a N/A change from a year earlier, with the FY2022 full-year figure at $24.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities for Q4 2022 stood at $24.0 million, up from $18.6 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for NTLA reached as high as $24.0 million in Q4 2022 and fell as low as $13000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Intellia Therapeutics | 1.32 Bn | 1.32 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 24.03 Mn |
| Sep 30, 2022 | 18.60 Mn |
| Jun 30, 2022 | 10.79 Mn |
| Mar 31, 2022 | 10.96 Mn |
| Dec 31, 2018 | 13,000.00 |
| Sep 30, 2018 | 52,000.00 |
| Jun 30, 2018 | 92,000.00 |
| Mar 31, 2018 | 131,000.00 |
| Dec 31, 2017 | 168,000.00 |
| Sep 30, 2017 | 201,000.00 |
| Jun 30, 2017 | 234,000.00 |
| Mar 31, 2017 | 378,000.00 |
| Dec 31, 2016 | 293,000.00 |
| Sep 30, 2016 | 306,000.00 |
| Jun 30, 2016 | 363,000.00 |
| Mar 31, 2016 | 349,000.00 |
| Dec 31, 2015 | 323,000.00 |